Our Tests


Also known as: Gene expression assay of breast cancer

« Back to test list


Gene expression assays are tests which measure the activity of different genes in a sample of tumour tissue. The pattern of gene activity in breast cancer can assist in the diagnosis of the type of breast cancer (luminal A, luminal B, HER2-enriched, and basal-like). The gene expression assay provided by Sonic Genetics is called “Prosigna”.

This is an assay for non-heritable mutations. It does not raise issues of ethics or consent that are different from most other investigations ordered in the routine care of a patient.

Clinical Utility

The Therapeutic Goods Administration limits the information that we can place in the public domain regarding the use of this test.

We would be pleased to provide detailed information to clinicians (please email info@sonicgenetics.com.au).

We recommend that patients seek further information from their doctors.


This test involves analysis of the activity of 50 genes

Test Method

RNA is extracted from a small section of formalin fixed tumour tissue, and RNA molecules from each of 50 genes are counted.

Test Ordering

This test should only be requested by the specialist responsible for managing a woman’s decision-making regarding chemotherapy. The sample required is formalin fixed, paraffin-embedded tissue (FFPE).

Special Instructions

There are specific sample requirements; pathologists are requested to contact the laboratory for details.



This test requires pre-payment. Please contact Sonic Genetics on 1800 010 447.

Medicare Rebate

This test is not rebated by Medicare. The laboratory assumes that the patient has provided informed financial consent for the test.

Turnaround Time

10 working days from receipt at testing laboratory

For Patients